top of page

PUBLICATION OF LATEST FINDINGS

  1. Man CH, Lam W, Dang CC, Zeng XY, Zheng LC, Chan NN, Ng NKL, Chan KC, Kwok TH, Ng TC, Leung WY, Huen M, Wong CC, So CWE, Dou Z, Goyama S, Bray MR, Mak TW, Leung AYH. Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML. Blood (2023) 142 (23): 2002–2015.

  2. Wang, D., Zheng, L., Cheng, B. Y. L., Sin, C. F., Li, R., Tsui, S. P., YI, X., Ma, A. C. H., He, B. L., Leung, A. Y. H. & Sun, X. 2023. Transgenic IDH2(R172K) and IDH2(R140Q) zebrafish models recapitulated features of human acute myeloid leukemia. Oncogene, 42, 1272-1281.

  3. Man, C. H., Zeng, X., Lam, W., Ng, T. C. C., Kwok, T. H., Dang, K. C. C., Leung, T. W. Y., Ng, N. K. L., Lam, S. S. Y., Cher, C. Y. & Leung, A. Y. H. 2022. Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication. Leukemia, 36, 1990-2001.

  4. Tsui SP, Ip HW, Saw NY, Zhang C, Cheung AK, Ng NK, Man CH, Lam SS, Tang WF, Lin CH, Cheng GH, Au CH, Ma ES, Chan TL, So CC, Ng MH, Cheng KC, Wong KF, Siu LP, Yip SF, Lin SY, Lau JS, Luk TH, Lee HK, Lau CK, Kho B, Sim JP, Kwong YL, Leung SY, Javed A, Leung AY. Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults. Blood Cancer Journal 2020 Oct 19;10(10):104.

  5. He BL, Yang N, Man CH, Ng NK, Cher CY, Leung HC, Kan LL, Cheng BY, Lam SS, Wang ML, Zhang CX, Kwok H, Cheng G, Sharma R, Ma AC, So CE, Kwong YL, Leung AY. Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia. EMBO Mol Med. 2020; 12(8):e12911.

  6. Lam SY, Ho ES, He BL, Wong WW, Cher CY, Ng NK, Man CH, Gill H, Cheung AM, Ip HW, So CC, Temburini J, So CW, Ho DN, Au CH, Chan TL, Ma ES, Liang R, Kwong YL, Leung AY. Homoharringtonine (omacetaxine mepessucinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Sci Transl Med 2016; 8(359): 359ra129.

  7. Cher CY, Leung GM, Au CH, Chan TL, Ma ES, Sim JP, Gill H, Lie AK, Liang R, Wong KF, Siu LL, Tsui CS, So CC, Wong HW, Yip SF, Lee HK, Liu HS, Lau JS, Luk TH, Lau CK, Lin SY, Kwong YL, Leung AY. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome. Blood Cancer J. 2016; 6(7): e442.

  8. Man CH, Fung TK, Wan H, Cher CY, Fan A, Ng N, Ho C, Wan TS, Tanaka T, So EC, Kwong YL, Leung AY. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. Blood. 2015; 125(25): 3928-3936.

  9. Shi X, He BL, Ma AC, Guo Y, Chi Y, Man CH, Zhang W, Zhang Y, Wen Z, Cheng T, Leung AY. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish. Blood. 2015;125(19):2974-84.

  10. Man CH, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood. 2014;123(16):2530-9.

  11. He BL, Shi X, Man CH, Ma AC, Ekker SC, Chow HC, So CW, Choi WW, Zhang W, Zhang Y, Leung AY. Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia. Blood. 2014;123(16):2518-29.

  12. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY. Sorafenib treatment of FLT3-ITD + acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012;119(22):5133-43.

  13. Ma AC, Fung TK, Lin RH, Chung MI, Yang D, Ekker SC, Leung AY. Methionine aminopeptidase 2 is required for HSC initiation and proliferation. Blood 2011;118(20):5448-57.

LATEST RESEARCH GRANTS

1. NSFC/RGC Joint Research Scheme 2021/22 Layman Summaries of Projects Fund (N_HKU745/21)

Deciphering recurrent mutation combinations in myelodysplasia syndromes using zebrafish – mechanistic and therapeutic insights

Year awarded: 2022 (4 years)

Amount (HKD): 1,185,561.00

Hong Kong Principal Investigator: Prof. Leung, Anskar Yu Hung (University of Hong Kong)

Mainland Principal Investigator: Prof Yiyue Zhang (South China University of Technology) 

 

2. Health and Medical Research Fund (08192066)

Develop a zebrafish model of human chronic myelomonocytic leukaemia (CMML) based on recurrent mutation combinations

Year awarded: 2021 (3 years)

Amount (HKD): 1,499,916.00

Principal Investigator: Prof Leung, Anskar Yu Hung 

​

3. Health and Medical Research Fund (08193106)

Modelling myeloproliferative neoplasms (MPNs) in a multi-colour transgenic zebrafish – mechanistic and therapeutic insights

Year awarded: 2021 (3 years)

Amount (HKD): 1,363,304.00

Principal Investigator: Dr Sun, Sally Xuan

 

4. Health and Medical Research Fund (08192166)

Targeting proton shifting by a novel MCT4 inhibitor in treating acute myeloid leukemia

Year awarded: 2022 (3 years)

Amount (HKD): 1,493,888.00

Principal Investigator: Dr Man Cheuk Him

 

5. Health and Medical Research Fund (08191906)

Targeting complex/monosomy karyotype acute myeloid leukaemia carrying TP53 mutations with PLK4 inhibitor- a mechanistic and therapeutic study

Year awarded: 2021 (3 years)

Amount (HKD): 1,397,780.00

Principal Investigator: Dr Ng, Nelson Ka Lam

 

6. Theme-based Research Scheme (T12-702/20-N)

Towards personalized and innovative treatment for acute myeloid leukaemia
Year awarded: 2020 (5 years)
Amount (HKD): 46,667,000.00

Principal Investigator: Prof Leung, Anskar Yu Hung
 

​

©2021 by The Leung Lab, Department of Medicine, The University of Hong Kong

bottom of page